Edwards Lifesciences (NYSE:EW) Updates Q2 Earnings Guidance

Edwards Lifesciences (NYSE:EW) issued an update on its second quarter earnings guidance on Thursday morning. The company provided earnings per share guidance of $0.67-0.71 for the period, compared to the consensus earnings per share estimate of $0.70. The company issued revenue guidance of $1.62-1.70 billion, compared to the consensus revenue estimate of $1.65 billion. Edwards Lifesciences also updated its FY 2024 guidance to 2.700-2.800 EPS.

Edwards Lifesciences Trading Down 1.8 %

Edwards Lifesciences stock traded down $1.58 during midday trading on Friday, reaching $86.43. The stock had a trading volume of 4,979,943 shares, compared to its average volume of 2,883,164. The company has a quick ratio of 2.40, a current ratio of 3.38 and a debt-to-equity ratio of 0.09. Edwards Lifesciences has a 52-week low of $60.57 and a 52-week high of $96.12. The firm has a market cap of $52.02 billion, a price-to-earnings ratio of 37.25, a price-to-earnings-growth ratio of 4.29 and a beta of 1.05. The company has a fifty day moving average of $90.28 and a 200 day moving average of $78.89.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, April 25th. The medical research company reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.02. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 23.34%. The company had revenue of $1.60 billion for the quarter, compared to analyst estimates of $1.58 billion. On average, analysts anticipate that Edwards Lifesciences will post 2.76 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on EW shares. Stifel Nicolaus increased their price objective on shares of Edwards Lifesciences from $83.00 to $85.00 and gave the stock a hold rating in a research report on Friday. Royal Bank of Canada raised their target price on shares of Edwards Lifesciences from $95.00 to $101.00 and gave the stock an outperform rating in a research report on Monday, April 15th. Mizuho raised their target price on shares of Edwards Lifesciences from $95.00 to $105.00 and gave the stock a buy rating in a research report on Thursday, April 11th. Piper Sandler raised their target price on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the stock a neutral rating in a research report on Friday. Finally, Bank of America raised shares of Edwards Lifesciences from a neutral rating to a buy rating in a research report on Thursday, March 7th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and ten have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of Moderate Buy and a consensus price target of $93.33.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,255 shares of the firm’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $78.29, for a total value of $567,993.95. Following the completion of the sale, the chief financial officer now directly owns 19,248 shares in the company, valued at $1,506,925.92. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,255 shares of the firm’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $78.29, for a total value of $567,993.95. Following the completion of the sale, the chief financial officer now directly owns 19,248 shares in the company, valued at $1,506,925.92. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Heisz Leslie Stone sold 7,056 shares of the firm’s stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $86.45, for a total transaction of $609,991.20. Following the completion of the sale, the director now owns 26,980 shares of the company’s stock, valued at $2,332,421. The disclosure for this sale can be found here. Insiders have sold a total of 194,004 shares of company stock valued at $17,166,254 over the last ninety days. 1.29% of the stock is owned by company insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.